190 related articles for article (PubMed ID: 21849050)
1. Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility.
Stavik B; Skretting G; Aasheim HC; Tinholt M; Zernichow L; Sletten M; Sandset PM; Iversen N
BMC Cancer; 2011 Aug; 11():357. PubMed ID: 21849050
[TBL] [Abstract][Full Text] [Related]
2. TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells.
Stavik B; Skretting G; Olstad OK; Sletten M; Dehli Vigeland M; Sandset PM; Iversen N
PLoS One; 2012; 7(10):e47184. PubMed ID: 23071754
[TBL] [Abstract][Full Text] [Related]
3. TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.
Gaud G; Iochmann S; Guillon-Munos A; Brillet B; Petiot S; Seigneuret F; Touzé A; Heuzé-Vourc'h N; Courty Y; Lerondel S; Gruel Y; Reverdiau P
J Cell Mol Med; 2011 Feb; 15(2):196-208. PubMed ID: 20015200
[TBL] [Abstract][Full Text] [Related]
4. TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.
Stavik B; Tinholt M; Sletten M; Skretting G; Sandset PM; Iversen N
J Hematol Oncol; 2013 Jan; 6():5. PubMed ID: 23320987
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of both TFPIα and TFPIβ induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells.
Stavik B; Skretting G; Sletten M; Sandset PM; Iversen N
Mol Carcinog; 2010 Nov; 49(11):951-63. PubMed ID: 20886581
[TBL] [Abstract][Full Text] [Related]
6. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.
Guo H; Lin Y; Zhang H; Liu J; Zhang N; Li Y; Kong D; Tang Q; Ma D
BMC Mol Biol; 2007 Dec; 8():110. PubMed ID: 18053161
[TBL] [Abstract][Full Text] [Related]
8. Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway.
Sawhney RS; Cookson MM; Omar Y; Hauser J; Brattain MG
J Biol Chem; 2006 Mar; 281(13):8497-510. PubMed ID: 16461767
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
Cai B; Chen W; Pan Y; Chen H; Zhang Y; Weng Z; Li Y
Prostate; 2017 Jul; 77(10):1057-1065. PubMed ID: 28631332
[TBL] [Abstract][Full Text] [Related]
10. Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.
Iochmann S; Bléchet C; Chabot V; Saulnier A; Amini A; Gaud G; Gruel Y; Reverdiau P
Clin Exp Metastasis; 2009; 26(5):457-67. PubMed ID: 19267203
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein binds to integrin α2 and Fcγ receptor I, leading to breast cell adhesion and breast cancer progression.
Kim ES; Kim SY; Koh M; Lee HM; Kim K; Jung J; Kim HS; Moon WK; Hwang S; Moon A
Oncogene; 2018 Jan; 37(1):28-38. PubMed ID: 28846105
[TBL] [Abstract][Full Text] [Related]
12. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action.
Wang S; Liu Q; Zhang Y; Liu K; Yu P; Liu K; Luan J; Duan H; Lu Z; Wang F; Wu E; Yagasaki K; Zhang G
Mol Cancer; 2009 Oct; 8():81. PubMed ID: 19796390
[TBL] [Abstract][Full Text] [Related]
13. Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer.
Van Slambrouck S; Jenkins AR; Romero AE; Steelant WF
Int J Oncol; 2009 Jun; 34(6):1717-26. PubMed ID: 19424590
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Das R; Mahabeleshwar GH; Kundu GC
J Biol Chem; 2004 Mar; 279(12):11051-64. PubMed ID: 14704150
[TBL] [Abstract][Full Text] [Related]
15. MDM2 and PSMA Play Inhibitory Roles in Metastatic Breast Cancer Cells Through Regulation of Matrix Metalloproteinases.
Bradbury R; Jiang WG; Cui YX
Anticancer Res; 2016 Mar; 36(3):1143-51. PubMed ID: 26977010
[TBL] [Abstract][Full Text] [Related]
16. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways.
Byun HJ; Hong IK; Kim E; Jin YJ; Jeoung DI; Hahn JH; Kim YM; Park SH; Lee H
J Biol Chem; 2006 Nov; 281(46):34833-47. PubMed ID: 16984917
[TBL] [Abstract][Full Text] [Related]
17. Oestrogen induced downregulation of TFPI expression is mediated by ERα.
Ali HO; Stavik B; Dørum E; Iversen N; Sandset PM; Skretting G
Thromb Res; 2014 Jul; 134(1):138-43. PubMed ID: 24785473
[TBL] [Abstract][Full Text] [Related]
18. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells.
Wang S; Zhong Z; Wan J; Tan W; Wu G; Chen M; Wang Y
Am J Chin Med; 2013; 41(1):177-96. PubMed ID: 23336515
[TBL] [Abstract][Full Text] [Related]
19. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Kunigal S; Lakka SS; Gondi CS; Estes N; Rao JS
Int J Cancer; 2007 Nov; 121(10):2307-16. PubMed ID: 17657740
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells.
Liu Y; Wang J; Wu M; Wan W; Sun R; Yang D; Sun X; Ma D; Ying G; Zhang N
Mol Cancer Res; 2009 Jun; 7(6):944-54. PubMed ID: 19531564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
